Overview
MNPR market data
Price History
MNPR price chart
Valuation & Profitability
- P/E (TTM)
- — Trailing twelve-month price-to-earnings ratio. Higher means the market is pricing in more growth. Negative or missing when earnings are negative.
- Forward P/E
- — P/E based on consensus forward EPS estimates. Lower versus trailing implies expected earnings growth.
- EPS (TTM)
- -$1.85 Diluted earnings per share over the trailing twelve months.
- Beta
- 1.45 Volatility relative to the index. 1.00 equals market, above 1 amplifies the broad-market move, below 1 dampens it.
- Dividend Yield
- — Annual dividend per share divided by current price. Zero or blank when the company does not pay a dividend.
- Profit Margin
- — Net income divided by revenue. Comparable within a sector, less so across sectors.
- 52w range
- $29.18 – $116.64 Lowest and highest closing prices over the past 52 weeks.
- Analyst Target
- — Mean of sell-side analyst 12-month price targets. Use as a sentiment gauge; targets are biased upward in aggregate.
Display-only. Refreshed once per symbol per 24 hours · source Twelve Data /statistics · market cap $722 · P/B 3.17.
Company news
HC Wainwright & Co. Maintains Buy on Monopar Therapeutics, Raises Price Target to $125Benzinga · Jul 22, 2026, 3:59 PM
Monopar Therapeutics Begins Rolling Submission Of FDA New Drug Application For ALXN1840 Albumin Tripartite Complex Activator To Treat Wilson DiseaseBenzinga · Jul 22, 2026, 12:02 PM
8-K filing — Monopar Therapeutics (MNPR)SEC EDGAR · Jul 22, 2026, 12:00 PM
Monopar Says FDA Grants Rare Pediatric Disease Designation To ALXN1840, Late-Stage Candidate For Treatment Of Wilson DiseaseBenzinga · Jun 30, 2026, 12:05 PM
Monopar Therapeutics To Present New Analyses From Phase 3 FoCus Randomized Clinical Trial Of ALXN1840 At EAN 2026.Benzinga · Jun 26, 2026, 8:15 PM
Monopar Presents Phase 2 ALXN1840 Data Demonstrating Liver Disease Stabilization and Neurologic Improvement in Treatment-Experienced Wilson Disease Patients at EASL 2026Globenewswire Inc · Jun 1, 2026, 11:15 AM
Monopar Therapeutics Publishes Phase 2 Study Demonstrating ALXN1840 Improves Copper Balance In Patients With Wilson DiseaseBenzinga · May 19, 2026, 9:40 PM
Monopar Therapeutics Reports First Quarter 2026 Financial Results and Provides Business UpdatesGlobenewswire Inc · May 14, 2026, 6:15 PM
Monopar Therapeutics Q1 EPS $(0.46) Beats $(0.83) EstimateBenzinga · May 14, 2026, 6:03 PM